[L&K Engineering] Announcement of cumulative disposal of the same securities exceeding NT$300 million
L&K Engineering announced the sale of 467,000 shares of PharmaEssentia for NT$321.6 million, realizing a disposal profit of approximately NT$282.5 million to enrich operating capital.
📋 Article Processing Timeline
- 📰 Published: May 15, 2026 at 09:00
- 🔍 Collected: May 16, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 16, 2026 at 09:35 (1h 35m after Collected)
1. Name of securities: Common stock of PharmaEssentia Corporation
2. Trading date: 2025/05/28 ~ 2026/05/15
3. Date of board of directors approval: Not applicable
4. Other approval dates: Handled according to company authority limits. May 15, 2026
5. Transaction volume, unit price, and total transaction amount:
Transaction volume: 467,000 shares
Unit price: Average NT$688.76 per share
Total transaction amount: NT$321,651,000
6. Profit (or loss) from disposal: Disposal profit NT$282,498,115
7. Relationship with the underlying company: None
8. Cumulative holding, amount, shareholding ratio, and restrictions: Remaining balance: 158,330 shares; Amount: NT$12,270,003; Shareholding ratio: 0.04%; Restrictions: None
9. Ratio of total securities investment to total assets and equity, and operating capital: Ratio to total assets: 31.82%; Ratio to equity: 78.91%; Operating capital: NT$5,711,366,634
10. Concrete purpose of disposal: To enrich operating capital and increase revenue.
11. Opinions of dissenting directors: None
12. Is this a related party transaction: No
13. Counterparty and relationship: None
14. Date of supervisor/audit committee approval: Not applicable
15. Date of previous announcement: Not applicable
16. Other matters: PharmaEssentia distributed 43,935 new shares as dividends in October 2025.
2. Trading date: 2025/05/28 ~ 2026/05/15
3. Date of board of directors approval: Not applicable
4. Other approval dates: Handled according to company authority limits. May 15, 2026
5. Transaction volume, unit price, and total transaction amount:
Transaction volume: 467,000 shares
Unit price: Average NT$688.76 per share
Total transaction amount: NT$321,651,000
6. Profit (or loss) from disposal: Disposal profit NT$282,498,115
7. Relationship with the underlying company: None
8. Cumulative holding, amount, shareholding ratio, and restrictions: Remaining balance: 158,330 shares; Amount: NT$12,270,003; Shareholding ratio: 0.04%; Restrictions: None
9. Ratio of total securities investment to total assets and equity, and operating capital: Ratio to total assets: 31.82%; Ratio to equity: 78.91%; Operating capital: NT$5,711,366,634
10. Concrete purpose of disposal: To enrich operating capital and increase revenue.
11. Opinions of dissenting directors: None
12. Is this a related party transaction: No
13. Counterparty and relationship: None
14. Date of supervisor/audit committee approval: Not applicable
15. Date of previous announcement: Not applicable
16. Other matters: PharmaEssentia distributed 43,935 new shares as dividends in October 2025.